Genetic Association Analysis of Anti-VEGF Treatment Response in Neovascular Age-Related Macular Degeneration
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Anti-VEGF treatment for neovascular age-related macular degeneration (nAMD) has been FDA-approved in 2004, and since then has helped tens of thousands of patients worldwide to preserve vision. Still, treatment responses vary widely, emphasizing the need for genetic biomarkers to robustly separate responders from non-responders. Here, we report the findings of an observational study compromising 179 treatment-naïve nAMD patients and their reaction to treatment after three monthly doses of anti-VEGF antibodies. We show that established criteria of treatment response such as visual acuity and central retinal thickness successfully divides our cohort into 128 responders and 51 non-responders. Nevertheless, retinal thickness around the fovea revealed significant reaction to treatment even in the formally categorized non-responders. To elucidate genetic effects underlying our criteria, we conducted an undirected genome-wide association study followed by a directed replication study of 30 previously reported genetic variants. Remarkably, both approaches failed to result in significant findings, suggesting study-specific effects were confounding the present and previous discovery studies. Of note, all studies so far are greatly underpowered, hampering interpretation of genetic findings. In consequence, we highlight the need for an extensive phenotyping study with sample sizes exceeding at least 15,000 to reliably assess anti-VEGF treatment responses in nAMD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, a 2022 comprehensive review of 41 observational series, 7 meta-analyses, and 5 GWAS reported no consistent patterns among the findings [40].”
From Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians. (2024) · cites this paper as [40]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · cited 1×
“Comparison of physiological and clinical parameters between study groups was conducted using a pairwise Wilcoxon test, adjusted for multiple testing based on the false discovery rate (FDR) approach [24].”
MethodA global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247 · cited 2×
“r904) [21], and then imputed to the 1000 Genomes Project Phase 3 reference panel [20] by IMPUTE2 (Version 2.”
BackgroundMethodThe variant call format and VCFtools
Danecek, P., Auton, A., Abecasis, G., Albers, C. A., Banks, E., DePristo, M. A., Handsaker, R. E., Lunter, G., Marth, G. T., Sherry, S. T., et al. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr330 · Cited by 16,200
Second-generation PLINK: rising to the challenge of larger and richer datasets
Chang, C. C., Chow, C. C., Tellier, L. C., Vattikuti, S., Purcell, S. M., & Lee, J. J. (2015) · Gigascience · doi:10.1186/s13742-015-0047-8 · Cited by 12,709
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711 · cited 1×
“Additionally, if the orientation of alleles was conflicting with the 1000 Genomes Project reference panel (Phase 3, release 20130502), strand orientation was switched [29].”
BackgroundRanibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331 · cited 1×
“Age-related macular degeneration (AMD) is a multifactorial disease with late-onset affecting central vision of millions of people worldwide [1].”
BackgroundA high-performance computing toolset for relatedness and principal component analysis of SNP data
Zheng, X., Levine, D., Shen, J., Gogarten, S. M., Laurie, C., & Weir, B. S. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts606 · Cited by 2,524 · cited 1×
“1) [18] using the snpgdsPCA [19] function based on 100,000 random genetic variants of each sample and the corresponding genotype information of the 1000 Genomes Project reference panel (Phase 3, release 20130502) [20].”
MethodIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Machiela, M. J., & Chanock, S. J. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv402 · Cited by 2,069 · cited 2×
“We applied LDlink [28] to remove genetic variants in high LD (R2 > 0.8).”
MethodInfluentialA linear complexity phasing method for thousands of genomes
Delaneau, O., Marchini, J., & Zagury, J.-F. (2012) · Nature Methods · doi:10.1038/nmeth.1785 · Cited by 1,850 · cited 1×
“r904) [21], and then imputed to the 1000 Genomes Project Phase 3 reference panel [20] by IMPUTE2 (Version 2.”
BackgroundFritsche, L. G., Igl, W., Bailey, J. N. C., Grassmann, F., Sengupta, S., Bragg-Gresham, J. L., Burdon, K. P., Hebbring, S. J., Wen, C., Gorski, M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3448 · Cited by 1,544 · cited 1×
“Disease risk is known to be conferred by environmental factors, such as smoking or ageing, as well as by genetic predisposition [2,3].”
BackgroundSelf-citationqqman: an R package for visualizing GWAS results using Q-Q and manhattan plots
Turner, S. D. (2014) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/005165 · Cited by 1,114 · cited 1×
“The R libraries ggplot2 [25] and qqman [26] were applied to visualize results.”
MethodGenotype Imputation with Thousands of Genomes
Howie, B., Marchini, J., & Stephens, M. (2011) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.111.001198 · Cited by 966
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849
A Simplified Severity Scale for Age-Related Macular Degeneration: AREDS Report No. 18
(2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.11.1570 · Cited by 807
Holz, F. G., Amoaku, W., Donate, J., Guymer, R. H., Kellner, U., Schlingemann, R. O., Weichselberger, A., & Staurenghi, G. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.12.019 · Cited by 413 · cited 1×
“Multiple treatment regimens for antibody applications are used, ranging from monthly doses to a pro re nata (PRN) or a treat and extend (TAE) strategy [6,8].”
Brantley, M. A., Fang, A. M., King, J. M., Tewari, A., Kymes, S. M., & Shiels, A. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.09.008 · Cited by 201 · cited 1×
“The observation of “non-responders” frequently raises the question of whether genetic variants could influence the treatment response and consequently may serve as biomarkers to distinguish or to predict outcome [13].”
BackgroundSchmidt-Erfurth, U., Klimscha, S., Waldstein, S. M., & Bogunović, H. (2017) · Eye · doi:10.1038/eye.2016.227 · Cited by 181 · cited 1×
“For example, retinal angiomatous proliferation (RAP) lesions (macular neovascularization type 3) present a distinct phenotype and have been reported to respond well to anti-VEGF treatment [40,41].”
BackgroundSimader, C., Ritter, M., Bolz, M., Deák, G. G., Mayr-Sponer, U., Golbaz, I., Kundi, M., & Schmidt-Erfurth, U. M. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.12.029 · Cited by 177 · cited 1×
“A number of clinical and observational studies consistently report that retinal fluid is sometimes only partially dissolved in individuals after treatment [9,10].”
BackgroundNagiel, A., Sarraf, D., Sadda, S. R., Spaide, R. F., Jung, J. J., Bhavsar, K. V., Ameri, H., Querques, G., & Freund, K. B. (2015) · Retina · doi:10.1097/iae.0000000000000488 · Cited by 147 · cited 1×
“For example, retinal angiomatous proliferation (RAP) lesions (macular neovascularization type 3) present a distinct phenotype and have been reported to respond well to anti-VEGF treatment [40,41].”
BackgroundQuantitative Analysis of OCT for Neovascular Age-Related Macular Degeneration Using Deep Learning
Moraes, G., Fu, D. J., Wilson, M., Khalid, H., Wagner, S. K., Korot, E., Ferraz, D., Faes, L., Kelly, C. J., Spitz, T., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.09.025 · Cited by 137
Kuan, V., Warwick, A., Hingorani, A. D., Tufail, A., Cipriani, V., Burgess, S., Sofat, R., Fritsche, L. G., Igl, W., Bailey, J. N. C., et al. (2021) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2021.4601 · Cited by 120 · cited 1×
“Disease risk is known to be conferred by environmental factors, such as smoking or ageing, as well as by genetic predisposition [2,3].”
BackgroundOCT Biomarkers in Neovascular Age‐Related Macular Degeneration: A Narrative Review
Metrangolo, C., Donati, S., Mazzola, M., Fontanel, L., Messina, W., D’alterio, G., Rubino, M., Radice, P., Premi, E., & Azzolini, C. (2021) · Journal of Ophthalmology · doi:10.1155/2021/9994098 · Cited by 110 · cited 1×
“Several studies suggest the inclusion of additional markers such as CRT or VA [36].”
BackgroundAI-based monitoring of retinal fluid in disease activity and under therapy
Schmidt-Erfurth, U. M., Reiter, G. S., Riedl, S., Seeböck, P., Vogl, W., Blodi, B. A., Domalpally, A., Fawzi, A. A., Jia, Y., Sarraf, D., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100972 · Cited by 108 · cited 2×
“In this context, the use of artificial intelligence may prove helpful in identifying subtle response patterns [39].”
BackgroundSustained Visual Acuity Loss in the Comparison of Age-Related Macular Degeneration Treatments Trials
Ying, G.-S., Kim, B. J., Maguire, M. G., Huang, J., Daniel, E., Jaffe, G. J., Grunwald, J. E., Blinder, K. J., Flaxel, C. J., Rahhal, F., et al. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.1019 · Cited by 107 · cited 1×
“Further, up to 10% of treated patients show even a worsening of symptoms [6,11,12].”
BackgroundMoore, C. M., Jacobson, S. A., & Fingerlin, T. E. (2019) · Human Heredity · doi:10.1159/000508558 · Cited by 84 · cited 1×
“Power analysis was conducted in R applying the package genpwr [30] based on varying parameters as mentioned in the respective results section.”
MethodChaudhary, V., Matonti, F., Zarranz‐Ventura, J., & Stewart, M. W. (2021) · Retina · doi:10.1097/iae.0000000000003283 · Cited by 64 · cited 1×
“A number of clinical and observational studies consistently report that retinal fluid is sometimes only partially dissolved in individuals after treatment [9,10].”
BackgroundLorés‐Motta, L., Riaz, M., Grunin, M. A., Corominas, J., van Asten, F., Pauper, M., Leenders, M., Richardson, A. J., Muether, P. S., Cree, A. J., et al. (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.2019 · Cited by 45 · cited 2×
“For example, Lorés-Motta et al. (2018) collected patient samples from several clinics and identified rs12138564 (1: 156,291,600) as a potential marker associated with anti-VEGF nAMD treatment response in a discovery phase including 679 individuals (p-value 5.7 × 10−07).”
BackgroundMethodInfluentialTsilimbaris, M. K., Gálvez, M. I. L., Gallego‐Pinazo, R., Margaron, P., & Lambrou, G. N. (2016) · Journal of Ophthalmology · doi:10.1155/2016/4367631 · Cited by 42 · cited 1×
“Further, up to 10% of treated patients show even a worsening of symptoms [6,11,12].”
BackgroundFauser, S., & Lambrou, G. N. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2014.11.002 · Cited by 41 · cited 3×
“To generate a comprehensive list of potential nAMD treatment-associated variants, we additionally included data from Fauser and Lambrou (2015) [14], a review covering all association data prior to 2014.”
BackgroundMethodResultInfluentialYamashiro, K., Mori, K., Honda, S., Kano, M., Yanagi, Y., Obana, A., Sakurada, Y., Sato, T., Nagai, Y., Hikichi, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09632-0 · Cited by 35
Riaz, M., Lorés-Motta, L., Richardson, A. J., Lu, Y., Montgomery, G., Omar, A., Koenekoop, R. K., Chen, J., Muether, P., Altay, L., et al. (2016) · Scientific Reports · doi:10.1038/srep37924 · Cited by 26
Zhou, Y., Chen, C., Wang, Y.-X., Tong, Y., Fang, X., Li, L., & Wang, Z. (2017) · BMC Ophthalmology · doi:10.1186/s12886-017-0487-2 · Cited by 23
Wang, Z., Zou, M., Chen, A., Liu, Z., Young, C. A., Wang, S., Zheng, D., & Jin, G. (2022) · Acta Ophthalmologica · doi:10.1111/aos.14970 · Cited by 22
Akiyama, M., Takahashi, A., Momozawa, Y., Arakawa, S., Miya, F., Tsunoda, T., Ashikawa, K., Oshima, Y., Yasuda, M., Yoshida, S., et al. (2018) · Journal of Human Genetics · doi:10.1038/s10038-018-0493-0 · Cited by 14
Chaudhary, V., Holz, F. G., Wolf, S., Midena, E., Souied, E. H., Allmeier, H., Lambrou, G., Machewitz, T., Mitchell, P., & the ARIES study investigators (2022) · Ophthalmology and Therapy · doi:10.1007/s40123-022-00491-1 · Cited by 14
Grunin, M. A., Beykin, G., Rahmani, E., Schweiger, R., Barel, G., Hagbi-Levi, S., Elbaz-Hayoun, S., Rinsky, B., Ganiel, M., Carmi, S., et al. (2020) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.61.2.48 · Cited by 9 · cited 1×
“Five GWAS have been conducted in the context of nAMD treatment [31–35], ranging in sample size from 295 [35] to 2058 [34], all based on a discovery and a replication cohort.”
Method
Research works printed but not linked: 2
- 25. Gómez-Rubio, V. ggplot2-Elegant Graphics for Data Analysis (2nd Edition). J. Stat. Softw. 2017, 77, 1-3. [CrossRef]
- (2021, December 09). Available online: https://pubmed.ncbi.nlm.nih.gov/.
Cited by
Latifi‐Navid, H., Behrooz, A. B., Jamehdor, S., Davari, M., Latifinavid, M., Zolfaghari, N., Piroozmand, S., Taghizadeh, S., Bourbour, M., Shemshaki, G., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16111555 · Cited by 18
Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians.
Nguyen, J., Brantley, & Schwartz, S. G. (2024) · Frontiers in Bioscience-Scholar · doi:10.31083/j.fbs1601003 · Cited by 12
“It has been suggested that a sample size of at least 15,000 patients would be necessary to definitively identify genetic associations with responses to anti-VEGF therapy [40].”
BackgroundLatest Development on Genetics of Common Retinal Diseases
Chen, L. J., Chen, Z. J., & Pang, C. P. (2023) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000592 · Cited by 7
Guymer, R. H., Silva, R., Ghadessi, M., Leal, S., Gashaw, I., Damask, A., Paulding, C., & Rittenhouse, K. D. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.8.17 · Cited by 6
“6,10,17 The largest body of evidence on genetic variants associated with treatment response is related to ARMS2/HTRA1 , CFH , and VEGFA , 6,10,17–19 but even here results are conflicting.”
García‐Quintanilla, L., Almuiña-Varela, P., Maroñas, O., Gil-Rodríguez, A., Rodríguez‐Cid, M. J., Gil‐Martínez, M., Abraldes, M. J., de Irazazabal, F. G.-U., González‐Barcia, M., Mondelo‐García, C., et al. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.13.34 · Cited by 6
“20,21 There is a lack of agreement in the pharmacogenetic studies of nAMD response to anti-VEGF treatment, because different periods have been studied such as one, three, 22,23 four, 24 five 25 or six 26 months when it comes to short-term response and 12 to 24 months to long-term response.”
Background
Metadata
- Authors
- Strunz, T., Pöllmann, M., Gamulescu, M.-A., Tamm, S., & Weber, B. H. F.
- Affiliations
- University of Regensburg (DE)
- University Hospital Regensburg (DE)
- Corresponding author
- Tamm, Svenja
- Weber, Bernhard H. F.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-05-29
- Volume
- 23
- Issue
- 11
- Pages
- 6094
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9181567
- OpenAlex
- W4281718306
- Cited by
- 10
- References
- 38
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 3
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- University of Regensburg Publication Server (University of Regensburg) (submittedVersion)
- Funders
- Institute of Human Genetics Regensburg, Germany (TG77)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- neovascular age-related macular degeneration, anti-VEGF therapy, treatment response, genetic biomarkers, genome-wide association study, retinal thickness, visual acuity, genetic variants
- MeSH terms
- Ranibizumab, Antibodies, Monoclonal, Humans, Macular Degeneration, Treatment Outcome, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Genome-Wide Association Study, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.